Global drug delivery company, pSivida
Limited announced that it has entered into an
evaluation agreement with an undisclosed large global medical device
company to evaluate cardiovascular delivery of drugs using
pSivida’s drug delivery technologies.
pSivida is a global bio-nanotech company committed to the
biomedical sector and the development of drug delivery products.
pSivida owns the rights to develop and commercialize a
modified form of silicon (porosified or nano-structured silicon) known
as BioSilicon™, which has applications in drug delivery,
wound healing, orthopedics, and tissue engineering. The most advanced
BioSilicon™ product, BrachySil™ delivers a
therapeutic, P32 directly to solid tumors and is presently in Phase II
clinical trials for the treatment of pancreatic cancer.